Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Pertuzumab in HER2-Positive Metastatic Breast Cancer

February 25th 2015

BOLERO-2: Everolimus Plus Exemestane in Resistant MBC

February 25th 2015

Role of Bevacizumab in Breast Cancer

February 25th 2015

Endocrine Therapy Resistance in Breast Cancer

February 25th 2015

CDK4/6 Inhibition in Metastatic Breast Cancer

February 25th 2015

Treating ER-Positive De Novo Metastatic Breast Cancer

February 25th 2015

Genetic Tests Offer New Tool for Tumor Assessment

February 25th 2015

Pathology, Oncology Collaboration in Breast Cancer

February 25th 2015

Predicting Risk of Recurrence in Breast Cancer

February 25th 2015

Reviewing Key Genomic Assays in Breast Cancer

February 25th 2015

Pathologist's Role in Genetic Testing for Breast Cancer

February 25th 2015

Role of Genetic Testing in Breast Cancer

February 25th 2015

Introduction: Impact of Molecular Subtyping in Breast Cancer

February 25th 2015

Dr. Edith Perez on BOLERO-1 Results in HER2-Positive Breast Cancer

February 24th 2015

Edith Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, compares the results of the BOLERO-1 and BOLERO-3 trials.

Swain Discusses Final Survival Analysis of CLEOPATRA Study

February 24th 2015

For additional insight on the CLEOPATRA trial and its implications for clinical practice, OncLive interviewed Sandra M. Swain, MD, Medical Director of the Washington Cancer Institute at MedStar Washington Hospital Center.

Unprecedented OS Benefit Cements Pertuzumab Regimen as Frontline Standard in HER2-Positive MBC

February 20th 2015

Frontline pertuzumab plus trastuzumab and docetaxel improved survival by nearly 16 months in metastatic HER2-positive breast cancer, according to results from the phase III CLEOPATRA study that are now published in The New England Journal of Medicine.

Slamon's Tenacity Advances the Field of Breast Cancer Research

February 19th 2015

Dennis J. Slamon, MD, PhD, has had an immeasurable impact on the treatment of women with breast cancer by developing trastuzumab (Herceptin) and helping to launch the era of targeted therapies. He was honored in the Breast Cancer category with a 2014 Giants of Cancer Careâ„¢ award, a program that the Intellisphere® Oncology Specialty Group launched to honor leaders in the field.

Chemobrain-It's Real, It's Complex, and the Science Is Still Evolving

February 17th 2015

Talk with almost any cancer survivor, and she/he is likely to bring up the topic of "chemobrain," that fuzzy, murky state that patients blame for impaired memory.

Lung Cancer Screening, Trabectedin in Soft Tissue Sarcoma, and More

February 12th 2015

Palbociclib: An Exciting New Option in Breast Cancer

February 12th 2015